Payment overview · 2025
General Payments
$1,024.52
55 reported records · 13 companies
Healthcare provider profile · identity verified
Danny Silver, MD
Allopathic & Osteopathic Physicians|Emergency Medicine · FORT SMITH, AR · NPI 1972582260
Verified facts
What the public records show
CMS Open Payments records show Danny Silver, MD received $1,024.52 in general payments during 2025 across 55 reported records.
Paratek Pharmaceuticals, Inc. accounted for 21.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 16 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Belbuca, Ingrezza, Movantik, Nurtec Odt, Relistor.
Collegium Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BELBUCA as an associated drug or biological on 17475 records involving 4385 distinct recipient NPIs. Public Medicare Part D data also shows 132 claims for Belbuca by this doctor in 2024.
Collegium Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Nucynta as an associated drug or biological on 230 records involving 95 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Nucynta by this doctor in 2024.
Neurocrine BioSciences, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported INGREZZA as an associated drug or biological on 126456 records involving 27390 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Ingrezza by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ABRYSVO as an associated drug or biological on 55380 records involving 31565 distinct recipient NPIs. Public Medicare Part D data also shows 67 claims for Abrysvo by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 192 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NURTEC ODT as an associated drug or biological on 217574 records involving 54025 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Nurtec Odt by this doctor in 2024.
Salix Pharmaceuticals, a division of Bausch Health US, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported RELISTOR as an associated drug or biological on 23206 records involving 6246 distinct recipient NPIs. Public Medicare Part D data also shows 40 claims for Relistor by this doctor in 2024.
Salix Pharmaceuticals, a division of Bausch Health US, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULANCE as an associated drug or biological on 2652 records involving 1501 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Trulance by this doctor in 2024.
Valinor Pharma, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOVANTIK as an associated drug or biological on 4139 records involving 1847 distinct recipient NPIs. Public Medicare Part D data also shows 196 claims for Movantik by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Paratek Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $223.03 | 21.8% | 13 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $188.43 | 18.4% | 12 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $156.27 | 15.2% | 7 | 2025 |
| Collegium Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $103.78 | 10.1% | 5 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $82.66 | 8.1% | 4 | 2025 |
| Valinor Pharma, LLC | Unresolved — no canonical attribution shown | $60.08 | 5.9% | 3 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $49.12 | 4.8% | 3 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $41.63 | 4.1% | 2 | 2025 |
| Tonix Medicines, Inc. | Unresolved — no canonical attribution shown | $33.41 | 3.3% | 2 | 2025 |
| Neurocrine BioSciences, Inc. | Unresolved — no canonical attribution shown | $25.83 | 2.5% | 1 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $24.67 | 2.4% | 1 | 2025 |
| VERTEX PHARMACEUTICALS INCORPORATED | Unresolved — no canonical attribution shown | $21.71 | 2.1% | 1 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $13.90 | 1.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,024.52 | 55 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| NUZYRA Normalized: nuzyra |
Drug | Paratek Pharmaceuticals, Inc. | $223.03 | 13 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $188.43 | 12 | 2025 |
Source payment records
|
|||||
| RELISTOR Normalized: relistor |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $131.61 | 6 | 2025 |
Source payment records
|
|||||
| Belbuca Normalized: belbuca |
Drug | Collegium Pharmaceutical, Inc. | $103.78 | 5 | 2025 |
Source payment records
|
|||||
| XHANCE Normalized: xhance |
Drug | Paratek Pharmaceuticals, Inc. | $97.37 | 7 | 2025 |
Source payment records
|
|||||
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $82.66 | 4 | 2025 |
Source payment records
|
|||||
| MOVANTIK Normalized: movantik |
Drug | Valinor Pharma, LLC | $60.08 | 3 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $55.53 | 3 | 2025 |
Source payment records
|
|||||
| XELJANZ Normalized: xeljanz |
Drug | PFIZER INC. | $34.37 | 2 | 2025 |
Source payment records
|
|||||
| TONMYA Normalized: tonmya |
Drug | Tonix Medicines, Inc. | $33.41 | 2 | 2025 |
Source payment records
|
|||||
| INGREZZA Normalized: ingrezza |
Drug | Neurocrine BioSciences, Inc. | $25.83 | 1 | 2025 |
Source payment records
|
|||||
| Symbravo Normalized: symbravo |
Drug | Axsome Therapeutics, Inc. | $24.67 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $24.66 | 1 | 2025 |
Source payment records
|
|||||
| JOURNAVX Normalized: journavx |
Drug | VERTEX PHARMACEUTICALS INCORPORATED | $21.71 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $14.75 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $14.75 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Belbuca belbuca |
2025 | Belbuca | 2024 | 132 | exact normalized | Medicare Part D |
| INGREZZA ingrezza |
2025 | Ingrezza | 2024 | 25 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MOVANTIK movantik |
2025 | Movantik | 2024 | 196 | exact normalized | Medicare Part D |
| NURTEC ODT nurtec odt |
2025 | Nurtec Odt | 2024 | 20 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| RELISTOR relistor |
2025 | Relistor | 2024 | 40 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Collegium Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | BELBUCA open payments reported associated product |
CMS Open Payments — General Payments 17475 supporting records · 4385 recipient NPIs · example record 1224105020 |
Belbuca · 2024 Exact normalized brand match · 1 Part D row |
132 | 36 |
| Collegium Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | Nucynta open payments reported associated product |
CMS Open Payments — General Payments 230 supporting records · 95 recipient NPIs · example record 1224105108 |
Nucynta · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| Neurocrine BioSciences, Inc. Exact reporting entity; no affiliate inference |
2025 | INGREZZA open payments reported associated product |
CMS Open Payments — General Payments 126456 supporting records · 27390 recipient NPIs · example record 1242766729 |
Ingrezza · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ABRYSVO open payments reported associated product |
CMS Open Payments — General Payments 55380 supporting records · 31565 recipient NPIs · example record 1228794147 |
Abrysvo · 2024 Exact normalized brand match · 1 Part D row |
67 | 67 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
192 | 16 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | NURTEC ODT open payments reported associated product |
CMS Open Payments — General Payments 217574 supporting records · 54025 recipient NPIs · example record 1228794063 |
Nurtec Odt · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC Exact reporting entity; no affiliate inference |
2025 | RELISTOR open payments reported associated product |
CMS Open Payments — General Payments 23206 supporting records · 6246 recipient NPIs · example record 1231775437 |
Relistor · 2024 Exact normalized brand match · 1 Part D row |
40 | 14 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC Exact reporting entity; no affiliate inference |
2025 | TRULANCE open payments reported associated product |
CMS Open Payments — General Payments 2652 supporting records · 1501 recipient NPIs · example record 1231775445 |
Trulance · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| Valinor Pharma, LLC Exact reporting entity; no affiliate inference |
2025 | MOVANTIK open payments reported associated product |
CMS Open Payments — General Payments 4139 supporting records · 1847 recipient NPIs · example record 1248445875 |
Movantik · 2024 Exact normalized brand match · 1 Part D row |
196 | 53 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 3292 | 890 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 2826 | 439 |
| Gabapentin | Gabapentin | 1313 | 321 |
| Tizanidine Hcl | Tizanidine Hcl | 1080 | 292 |
| Oxycodone Hcl | Oxycodone Hcl | 858 | 194 |
| Morphine Sulfate Er | Morphine Sulfate | 692 | 111 |
| Levothyroxine Sodium | Levothyroxine Sodium | 603 | 42 |
| Pregabalin | Pregabalin | 585 | 148 |
| Morphine Sulfate | Morphine Sulfate | 472 | 78 |
| Atorvastatin Calcium | Atorvastatin Calcium | 441 | 62 |
| Baclofen | Baclofen | 381 | 93 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 347 | 100 |
| Buspirone Hcl | Buspirone Hcl | 338 | 51 |
| Buprenorphine | Buprenorphine | 319 | 80 |
| Tramadol Hcl | Tramadol Hcl | 283 | 114 |
| Naloxone Hcl | Naloxone Hcl | 267 | 243 |
| Amitriptyline Hcl | Amitriptyline Hcl | 240 | 67 |
| Trazodone Hcl | Trazodone Hcl | 233 | 45 |
| Amlodipine Besylate | Amlodipine Besylate | 231 | 32 |
| Furosemide | Furosemide | 230 | 35 |
| Methocarbamol | Methocarbamol | 227 | 69 |
| Diclofenac Sodium | Diclofenac Sodium | 221 | 76 |
| Pantoprazole Sodium | Pantoprazole Sodium | 216 | 38 |
| Gemtesa | Vibegron | 207 | 14 |
| Metoprolol Tartrate | Metoprolol Tartrate | 204 | 28 |
| Movantik | Naloxegol Oxalate | 196 | 53 |
| Meloxicam | Meloxicam | 193 | 53 |
| Potassium Chloride | Potassium Chloride | 193 | 25 |
| Eliquis | Apixaban | 192 | 16 |
| Quetiapine Fumarate | Quetiapine Fumarate | 184 | 22 |
| Linzess | Linaclotide | 178 | 56 |
| Clopidogrel | Clopidogrel Bisulfate | 145 | 19 |
| Carvedilol | Carvedilol | 140 | 20 |
| Ondansetron Odt | Ondansetron | 133 | 62 |
| Belbuca | Buprenorphine Hcl | 132 | 36 |
| Celecoxib | Celecoxib | 132 | 50 |
| Lactulose | Lactulose | 129 | 30 |
| Xtampza Er | Oxycodone Myristate | 128 | 28 |
| Divalproex Sodium | Divalproex Sodium | 123 | 12 |
| Tamsulosin Hcl | Tamsulosin Hcl | 121 | 19 |
| Mirtazapine | Mirtazapine | 116 | 29 |
| Losartan Potassium | Losartan Potassium | 112 | 16 |
| Jardiance | Empagliflozin | 110 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 103 | 30 |
| Metformin Hcl | Metformin Hcl | 102 | 14 |
| Promethazine Hcl | Promethazine Hcl | 100 | 30 |
| Ondansetron Hcl | Ondansetron Hcl | 99 | 33 |
| Sertraline Hcl | Sertraline Hcl | 96 | 18 |
| Lorazepam | Lorazepam | 95 | 25 |
| Memantine Hcl | Memantine Hcl | 92 | suppressed |
| Fentanyl | Fentanyl | 91 | 13 |
| Donepezil Hcl | Donepezil Hcl | 90 | 11 |
| Lisinopril | Lisinopril | 88 | 19 |
| Fluoxetine Hcl | Fluoxetine Hcl | 87 | 12 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 83 | 11 |
| Sucralfate | Sucralfate | 82 | suppressed |
| Prednisone | Prednisone | 79 | 47 |
| Lidocaine | Lidocaine | 72 | 31 |
| Topiramate | Topiramate | 72 | 11 |
| Methadone Hcl | Methadone Hcl | 71 | 12 |
| Olanzapine | Olanzapine | 71 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 71 | suppressed |
| Famotidine | Famotidine | 70 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 68 | 19 |
| Abrysvo | Rsv Vacc, Pref A And Pref B/Pf | 67 | 67 |
| Allopurinol | Allopurinol | 65 | suppressed |
| Levetiracetam | Levetiracetam | 65 | suppressed |
| Orphenadrine Citrate Er | Orphenadrine Citrate | 65 | 19 |
| Albuterol Sulfate | Albuterol Sulfate | 64 | 13 |
| Lubiprostone | Lubiprostone | 62 | suppressed |
| Clonazepam | Clonazepam | 59 | 14 |
| Montelukast Sodium | Montelukast Sodium | 59 | 12 |
| Sumatriptan Succinate | Sumatriptan Succinate | 59 | 17 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 58 | 11 |
| Alprazolam | Alprazolam | 57 | suppressed |
| Simvastatin | Simvastatin | 57 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 56 | 23 |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 55 | 15 |
| Warfarin Sodium | Warfarin Sodium | 55 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 54 | suppressed |
| Xarelto | Rivaroxaban | 54 | suppressed |
| Omeprazole | Omeprazole | 52 | 14 |
| Hydromorphone Hcl | Hydromorphone Hcl | 50 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 50 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 48 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 47 | suppressed |
| Metoprolol Succinate | Metoprolol Succinate | 46 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 44 | 11 |
| Risperidone | Risperidone | 43 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 42 | suppressed |
| Ibuprofen | Ibuprofen | 42 | 12 |
| Torsemide | Torsemide | 42 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 41 | suppressed |
| Relistor | Methylnaltrexone Bromide | 40 | 14 |
| Tradjenta | Linagliptin | 39 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 38 | 26 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 37 | 13 |
| Diltiazem Hcl | Diltiazem Hcl | 35 | suppressed |
| Fluconazole | Fluconazole | 35 | 19 |
| Pioglitazone Hcl | Pioglitazone Hcl | 35 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 34 | 12 |
| Aripiprazole | Aripiprazole | 33 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 33 | suppressed |
| Nifedipine Er | Nifedipine | 33 | suppressed |
| Azithromycin | Azithromycin | 32 | 17 |
| Cephalexin | Cephalexin | 31 | 20 |
| Citalopram Hbr | Citalopram Hydrobromide | 31 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 30 | suppressed |
| Diazepam | Diazepam | 29 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 27 | 21 |
| Clonidine Hcl | Clonidine Hcl | 27 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 26 | suppressed |
| Medroxyprogesterone Acetate | Medroxyprogesterone Acetate | 26 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 26 | suppressed |
| Ingrezza | Valbenazine Tosylate | 25 | suppressed |
| Belsomra | Suvorexant | 24 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 24 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 24 | suppressed |
| Hysingla Er | Hydrocodone Bitartrate | 24 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 24 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 24 | suppressed |
| Januvia | Sitagliptin Phosphate | 23 | suppressed |
| Myrbetriq | Mirabegron | 23 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 22 | suppressed |
| Lamotrigine | Lamotrigine | 22 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 22 | suppressed |
| Vraylar | Cariprazine Hcl | 22 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 21 | suppressed |
| Trulance | Plecanatide | 21 | suppressed |
| Atenolol | Atenolol | 20 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 20 | suppressed |
| Glipizide Er | Glipizide | 20 | suppressed |
| Nurtec Odt | Rimegepant Sulfate | 20 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 19 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 19 | suppressed |
| Rifampin | Rifampin | 19 | suppressed |
| Spironolactone | Spironolactone | 19 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 18 | suppressed |
| Ethambutol Hcl | Ethambutol Hcl | 18 | suppressed |
| Haloperidol | Haloperidol | 18 | suppressed |
| Nitroglycerin | Nitroglycerin | 18 | 12 |
| Glimepiride | Glimepiride | 17 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 17 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 17 | suppressed |
| Premarin | Estrogens, Conjugated | 17 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 17 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 16 | suppressed |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 16 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 15 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 15 | suppressed |
| Levofloxacin | Levofloxacin | 15 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 15 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 15 | suppressed |
| Admelog Solostar | Insulin Lispro | 14 | suppressed |
| Amantadine | Amantadine Hcl | 14 | suppressed |
| Amoxicillin | Amoxicillin | 14 | suppressed |
| Multaq | Dronedarone Hcl | 14 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 14 | suppressed |
| Nucynta | Tapentadol Hcl | 14 | suppressed |
| Nystatin | Nystatin | 14 | 12 |
| Oxycontin | Oxycodone Hcl | 14 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 14 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 14 | suppressed |
| Benazepril-Hydrochlorothiazide | Benazepril/Hydrochlorothiazide | 13 | suppressed |
| Buprenorphine Hcl | Buprenorphine Hcl | 13 | suppressed |
| Bupropion Xl | Bupropion Hcl | 13 | suppressed |
| Dayvigo | Lemborexant | 13 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 13 | suppressed |
| Naproxen | Naproxen | 13 | suppressed |
| Novolog Flexpen | Insulin Aspart | 13 | suppressed |
| Paliperidone Er | Paliperidone | 13 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 12 | suppressed |
| Budesonide | Budesonide | 12 | suppressed |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 12 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 12 | 11 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 12 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 12 | suppressed |
| Tobramycin-Dexamethasone | Tobramycin/Dexamethasone | 12 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 11 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 11 | suppressed |
| Copaxone | Glatiramer Acetate | 11 | suppressed |
| Fenofibrate | Fenofibrate | 11 | suppressed |
| Glipizide | Glipizide | 11 | suppressed |
| Lacosamide | Lacosamide | 11 | suppressed |
| Methotrexate | Methotrexate Sodium | 11 | suppressed |
| Minoxidil | Minoxidil | 11 | suppressed |
| Phenytoin | Phenytoin | 11 | suppressed |
| Sulfasalazine Dr | Sulfasalazine | 11 | suppressed |
| Vancomycin Hcl | Vancomycin/Water For Inj (Peg) | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,024.52 · 55 records | Paratek Pharmaceuticals, Inc. | AUSTEDO XR, Belbuca, CAPLYTA, INGREZZA, JOURNAVX, MOVANTIK, NURTEC ODT, NUZYRA, RELISTOR, REXULTI, Symbravo, TONMYA, XELJANZ, XHANCE, XIFAXAN, ZAVZPRET | 9 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Belbuca play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Collegium Pharmaceutical, Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error